ID: ALA2391037

Max Phase: Preclinical

Molecular Formula: C21H22ClN3O5S

Molecular Weight: 463.94

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC[C@H]1CN(c2ccc(N3CCC(C(=O)O)CC3)cc2)C(=O)O1)c1ccc(Cl)s1

Standard InChI:  InChI=1S/C21H22ClN3O5S/c22-18-6-5-17(31-18)19(26)23-11-16-12-25(21(29)30-16)15-3-1-14(2-4-15)24-9-7-13(8-10-24)20(27)28/h1-6,13,16H,7-12H2,(H,23,26)(H,27,28)/t16-/m0/s1

Standard InChI Key:  NTHTVBYMCWQXSW-INIZCTEOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 463.94

Molecular Weight (Monoisotopic): 463.0969

AlogP: 3.46

#Rotatable Bonds: 6

Polar Surface Area: 99.18

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.14

CX Basic pKa: 5.04

CX LogP: 2.35

CX LogD: 0.42

Aromatic Rings: 2

Heavy Atoms: 31

QED Weighted: 0.68

Np Likeness Score: -1.56

References

1. Trstenjak U, Ilaš J, Kikelj D..  (2013)  Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.,  64  [PMID:23644213] [10.1016/j.ejmech.2013.03.056]

2. Trstenjak U, Ilas J, Kikelj D.  (2014)  Transformation of a selective factor Xa inhibitor rivaroxaban into a dual factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety,  5  (2): [10.1039/C3MD00250K]

Source

Source(1):

• Scientific Literature